NF-κB-IN-20
NF-κB-IN-20 is an orally active NF-κB inhibitor. NF-κB-IN-20 directly binds to the Keap1 protein, activating the Keap1/Nrf2/HO-1 antioxidant pathway, and simultaneously inhibiting the NF-κB inflammatory pathway, thereby synergistically reducing oxidative stress and inflammatory responses. NF-κB-IN-20 M11 inhibits the expression of IL-6, IL-1β, and TNF-α, significantly reduces the level of ROS, and restores the mitochondrial membrane potential. NF-κB-IN-20 can be used for the study of acute lung injury (ALI).
For research use only. We do not sell to patients.
- Formula: C21H23NO4
- Molecular Weight:353.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
NF-κB |
IL-6 |
IL-1β |
HO-1 |
NF-κB-IN-20 (Compound M11) (0.01‑100 μM, 5 h) exhibits good in vitro safety (CC50 > 100 μM) in LPS (HY-D1056)-induced Raw264.7 cells, attenuates the mRNA expression levels of the inflammatory and oxidative stress markers IL-6 (IC50 = 6.55 μM), IL-1β, TNF-α, and SOD in a dose-dependent manner and inhibits ROS expression, enhances mitochondrial membrane potential, therefore mitigating LPS-induced cellular damage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Raw264.7 cells
-
Concentration:25, 50 and 100 μM
-
Incubation Time:1 h and stimulated with LPS for 4 h.
-
Result:Reduced the mRNA expressions of IL-6, IL-1β, and TNF-α and increased the mRNA expression of SOD.
NF-κB-IN-20 (15-60 mg/kg, i.g., once daily for 7 days) enhances sputum secretion and mitigated coughing in mice, thereby contributing to the management of pulmonary diseases[1].
NF-κB-IN-20 (500 mg/kg, i.g., single dose) exhibits good in vivo safety profile in SD rats during the 14-day During the 14-day observation period[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LPS induced ALI model established in five-to six-week-old male BALB/c mice[1]
-
Dosage:15, 30 and 60 mg/kg
-
Administration:Oral gavage (i.g.), once daily for 7 days
-
Result:Significantly reduced the total number of inflammatory cells in BALF. Enhanced the activities of SOD and GSH-Px in lung tissue, while reducing the level of ROS, effectively reversing the oxidative stress caused by LPS. Improved the pathological phenomena such as inflammatory cell infiltration, destruction of alveolar structure, and thickening of alveolar septa.
Inhibited the expression of M1-type macrophage markers (iNOS, CD86), while promoting the expression of M2-type markers (Arg-1, CD163).
-
Animal Model:Cecal puncture induced ALI model established in five-to six-week-old male BALB/c mice[1]
-
Dosage:15, 30 and 60 mg/kg
-
Administration:Oral gavage (i.g.), once daily for 7 days
-
Result:Alleviated lung injury caused by sepsis infection.
Ameliorated inflammatory cell infiltration, alleviated alveolar atrophy, and inhibited collagen formation and fibrosis.
Reversed the expression of inflammatory cytokine and oxidative stress related factors.
-
Animal Model:5 % ammonia-induced cough assay established in five-to six-week-old male BALB/c mice[1]
-
Dosage:15, 30 and 60 mg/kg
-
Administration:Oral gavage (i.g.), once daily for 7 days
-
Result:Demonstrated a significant increase in phenol red secretion in the BALF. Led to a prolonged cough latency period and a decreased frequency of coughs.
Chemical Information
-
Molecular Weight 353.41
-
Formula C21H23NO4
-
SMILES
O=C(N(C)/C=C\C1=CC=CC=C1)/C=C/C2=CC(OC)=C(OC)C(OC)=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz